Q-omics provides the consensus-scored SDC1 profile across patient tissues and cancer cell-line models. SDC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SDC1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SDC1 RNA expression shows 17,560 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where SDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDC1 survival associations across molecular data types. SDC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDC1 RNA expression–survival associations across cancer types. High SDC1 expression shows unfavorable associations in BRCA, MESO, CHOL, LGG, PAAD and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SDC1 RNA expression.
This table summarizes SDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDC1 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, THCA, BLCA and LUSC. The KIRC box plot shows higher SDC1 RNA expression in normal versus tumor tissue (log2 FC = −1.637, t-test p < 0.001).
This table shows molecular features associated with SDC1 in patient tissues and cancer cell lines. In patient samples, SDC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
